Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Selecting DLBCL patients for CAR T-cell therapies

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses how patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) are selected for CAR T-cell therapies and the associated challenges. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).